Aprea Therapeutics reports preliminary cash balance of $21.6M as of Dec 31, 2023

Aprea Therapeutics, Inc.

Preliminary cash, cash equivalents, and restricted cash expected to be approximately $21.6 million as of December 31, 2023.
Estimate is unaudited, preliminary, and subject to change upon completion of the year-end financial close process.
Company has not yet completed its financial closing procedures; independent auditor has not reviewed the estimate.
President and CEO Oren Gilad signed the filing; no further financial results or guidance provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.